Nexstim secures SEK 31.5 million in warrants and a directed issue

21 oktober 2019

Nexstim is a personalised neuromodulation company focused on approval and commercialisation of its therapeutic device (NBT® system) based on its unique SmartFocus® TMS (transcranial magnetic stimulation) technology for use in depression and chronic pain.

Nexstim secured the strike of the company’s outstanding warrants through subscription and underwriting commitments and decided on an additional directed issue, altogether securing approximately SEK 31.5 million in proceeds for continued commersialisation of its Navigated Brain Therapy system for depression, among other things.

Augment is acting financial advisor to Nexstim in connection with the transaction.

Read full press release here